Could changing up regulatory requirements for Alzheimer’s drugs help give desperate patients new options for treatment?
A group of researchers and patient advocates think so. They authored a paper that argues that the Food and Drug Administration should evaluate Alzheimer’s drugs for efficacy in either cognition or function — but not both.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Obviously Klunk never worked in pharma. 30 years of experience has taught me that getting marginally efficacious drugs approved, then charging obscenely high prices before it is concluded that your drug is a dud is a good business model, because everybody who made their six figure bonuses along the way will be long gone by the time the poo hits the fan.
You should point out that this is really a lobbying group: Registered on 03/26/2017 by Connect 4 Strategies, LLC: http://bit.ly/2pBDMdf